http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference
-
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
-
Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System
-
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
-
Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
-
Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE Pulsed Field Ablation System
-
Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation
-
Boston Scientific (BSX) Closes Acquisition of Relievant Medsystems
-
Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
-
Boston Scientific to Participate in Stifel's 2023 Healthcare Conference
-
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023
-
Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
-
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism
-
Boston Scientific Announces Conference Call Discussing Third Quarter 2023 Results
-
Boston Scientific (BSX) to Acquire Relievant Medsystems for Over $850 Million
-
Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
-
Boston Scientific (BSX) Announces FDA Approval for the Latest-Generation WATCHMAN FLX Pro Left Atrial Appendage Closure Device
-
Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device
-
Boston Scientific Announces 2023 Investor Day Meeting and Conference Call Discussing Third Quarter 2023 Results
-
Boston Scientific (BSX) Reports ADVENT Study of the FARAPULSE Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints
-
ADVENT Study of the FARAPULSE™ Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints
-
Boston Scientific Receives FDA Approval for the POLARx™ Cryoablation System
-
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2023
-
Boston Scientific Announces Conference Call Discussing Second Quarter 2023 Results
-
Boston Scientific (BSX) Appoints Jessica L. Mega and Susan E. Morano to its Board
-
Boston Scientific Elects Dr. Jessica L. Mega and Susan E. Morano to Board of Directors
-
Boston Scientific Announces Conversion Date of Series A Mandatory Convertible Preferred Stock
-
Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies
-
Boston Scientific to Participate in Bernstein's 39th Annual Strategic Decisions Conference
-
Boston Scientific Announces Results for First Quarter 2023
-
Boston Scientific Reports New Progress With Action for a Healthier, More Equitable World
-
Boston Scientific Announces Conference Call Discussing First Quarter 2023 Results
-
Boston Scientific to Participate in Citi's 2023 Healthcare Services, MedTech, Tools & HCIT Conference
-
Boston Scientific (BSX) Receives FDA Clearance for LithoVue
-
Boston Scientific Receives FDA Clearance for LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System
-
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022
-
Boston Scientific to Participate in J.P. Morgan Healthcare Conference and Announces Conference Call Discussing Fourth Quarter 2022 Results
-
Boston Scientific (BSX) to acquire majority stake in Acotec Scientific
-
Boston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited
-
Boston Scientific (BSX) to Acquire Apollo Endosurgery (APEN) for $10 Per Share, $615 million Deal
-
Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.
-
Late-Breaking Post-Market Study Data Reinforce Clinical Procedural Success and Safety of the ACURATE neo2™ Aortic Valve System
-
Boston Scientific Announces Upcoming Conference Schedule
-
Boston Scientific Announces Results for Third Quarter 2022
-
Boston Scientific Announces Conference Call Discussing Third Quarter 2022 Results
-
Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with SENTINEL™ Cerebral Protection System
-
Nordson Corporation Appoints Milton Morris to Board of Directors
-
Boston Scientific (BSX) Granted FDA Approval for Expanded Labeling of WATCHMAN FLX LAAC
-
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
-
Boston Scientific Announces Upcoming Conference Schedule

